Henning Hanken1, Alexander Gröbe1, Max Heiland1, Ralf Smeets1, Lan Kluwe1, Johannes Wikner1, Robert Koehnke1, Ahmed Al-Dam1, Wolfgang Eichhorn2,3. 1. Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, 52 Martinistrasse, Hamburg, 20246, Germany. 2. Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, 52 Martinistrasse, Hamburg, 20246, Germany. w.eichhorn@uke.de. 3. Department of Oral and Maxillofacial Surgery, General Hospital Balingen, 30 Tuebinger Strasse, Balingen, 72336, Germany. w.eichhorn@uke.de.
Abstract
OBJECTIVES: The purpose of this study was to assess the risk of postoperative bleeding complications after oral procedures performed under continued mono or dual anticoagulation therapy with rivaroxaban (and aspirin). METHODS: This retrospective single-center observational study included 52 oral procedures performed under continued oral anticoagulant therapy with rivaroxaban (20 mg/day). Among them, two procedures were performed under continued dual therapy with aspirin (100 mg/day) added to the regimen. Postoperative bleeding events were compared with 285 oral procedures in patients without any anticoagulation/antiplatelet therapy. RESULTS: Postoperative bleeding complications after oral surgery occurred significantly more often in patients under continued rivaroxaban therapy (11.5 %) than in the control cases without anticoagulation/antiplatelet medication (0.7 %). All of the bleeding events were manageable: Two of them were treated with local compression, three by applying new fibrin glue with (one case) or without (two cases) secondary sutures, one occurred during a weekend and was therefore treated under inpatient conditions with suture replacement. All postoperative bleeding episodes occurred during the first postoperative week. CONCLUSIONS: According to our data, continued anticoagulation therapy with rivaroxaban significantly increases postoperative bleeding risk for oral surgical procedures, although the bleeding events were manageable. CLINICAL RELEVANCE: Oral surgeons, cardiologists, general physicians, and patients should be aware of the increased bleeding risk after oral surgical procedures. Close observation up to 1 week postoperatively is advisable to prevent excessive bleeding.
OBJECTIVES: The purpose of this study was to assess the risk of postoperative bleeding complications after oral procedures performed under continued mono or dual anticoagulation therapy with rivaroxaban (and aspirin). METHODS: This retrospective single-center observational study included 52 oral procedures performed under continued oral anticoagulant therapy with rivaroxaban (20 mg/day). Among them, two procedures were performed under continued dual therapy with aspirin (100 mg/day) added to the regimen. Postoperative bleeding events were compared with 285 oral procedures in patients without any anticoagulation/antiplatelet therapy. RESULTS:Postoperative bleeding complications after oral surgery occurred significantly more often in patients under continued rivaroxaban therapy (11.5 %) than in the control cases without anticoagulation/antiplatelet medication (0.7 %). All of the bleeding events were manageable: Two of them were treated with local compression, three by applying new fibrin glue with (one case) or without (two cases) secondary sutures, one occurred during a weekend and was therefore treated under inpatient conditions with suture replacement. All postoperative bleeding episodes occurred during the first postoperative week. CONCLUSIONS: According to our data, continued anticoagulation therapy with rivaroxaban significantly increases postoperative bleeding risk for oral surgical procedures, although the bleeding events were manageable. CLINICAL RELEVANCE: Oral surgeons, cardiologists, general physicians, and patients should be aware of the increased bleeding risk after oral surgical procedures. Close observation up to 1 week postoperatively is advisable to prevent excessive bleeding.
Authors: Wolfgang Eichhorn; Jens Burkert; Oliver Vorwig; Marco Blessmann; Georg Cachovan; Jürgen Zeuch; Marc Eichhorn; Max Heiland Journal: Clin Oral Investig Date: 2011-12-13 Impact factor: 3.573
Authors: Gerardo Gómez-Moreno; Antonio Aguilar-Salvatierra; Esther Fernández-Cejas; Rafael Arcesio Delgado-Ruiz; Aleksa Markovic; José Luis Calvo-Guirado Journal: Clin Oral Implants Res Date: 2015-06-15 Impact factor: 5.977
Authors: Henning Hanken; Ferdinand Tieck; Lan Kluwe; Ralf Smeets; Max Heiland; Clarissa Precht; Marc Eichhorn; Wolfgang Eichhorn Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2014-09-16
Authors: Alexander Gröbe; Meike Fraederich; Ralf Smeets; Max Heiland; Lan Kluwe; Jürgen Zeuch; Martina Haase; Johannes Wikner; Henning Hanken; Jan Semmusch; Ahmed Al-Dam; Wolfgang Eichhorn Journal: Biomed Res Int Date: 2015-01-06 Impact factor: 3.411
Authors: Benjamin A Steinberg; Eric D Peterson; Sunghee Kim; Laine Thomas; Bernard J Gersh; Gregg C Fonarow; Peter R Kowey; Kenneth W Mahaffey; Matthew W Sherwood; Paul Chang; Jonathan P Piccini; Jack Ansell Journal: Circulation Date: 2014-12-12 Impact factor: 29.690
Authors: Guido Galletti; Fortunato Alfonsi; Angelo Raffaele; Nicola Alberto Valente; Sibylle Chatelain; Roni Kolerman; Chiara Cinquini; Stefano Romeggio; Giovanna Iezzi; Antonio Barone Journal: Int J Environ Res Public Health Date: 2020-06-26 Impact factor: 3.390
Authors: Mattia Manfredini; Pier Paolo Poli; Luca Creminelli; Alberto Porro; Carlo Maiorana; Mario Beretta Journal: J Clin Med Date: 2021-11-25 Impact factor: 4.241
Authors: Eveline T Engelen; Roger Eg Schutgens; Evelien P Mauser-Bunschoten; Robert Jj van Es; Karin Pm van Galen Journal: Cochrane Database Syst Rev Date: 2018-07-02